The ‘magic' pigmentation serum that sold every two MINUTES on launch day is finally back in stock - and it transforms skin in weeks
Tired of battling stubborn hyperpigmentation, dark spots and lingering redness? The new Hyperpigmentation Serum from Skin Rocks might just be your skincare game-changer.
Clinically proven to fade marks in as little as two weeks, this powerhouse formula sold out within five days of launching – and with one selling every two minutes on launch day, it's safe to say people are obsessed.
Skin Rocks The Hyperpigmentation Serum, 30ml
A new product from the brand but already boasting dozens of five-star reviews, the Skin Rocks Hyperpigmentation Serum is designed to reduce even the trickiest pigmentation in as little as two weeks.
Clinically proven to treat a huge array of hyperpigmentation and dark marks, it's been formulated with a carefully curated blend of actives to help reduce the appearance of marks while increasing radiance in all skin tones and types.
£85 Shop
Whether you struggle with post-breakout marks, stubborn redness or melasma, you need a skincare product that'll help you tackle it all while leaving your skin looking healthy and radiant. That's where The Hyperpigmentation Serum from Skin Rocks comes in.
A new product from the brand but already boasting dozens of five-star reviews, this sell-out serum is a must for those after a fast solution to dullness, uneven skin tone and dark spots.
'I have sun damage and red marks from old spots so am using 2 pumps in the evening, I have noticed that after just two weeks of use my skin looks considerably clearer,' raved one five-star reviewer. 'I can also say that after just one use, I woke up in the morning to glowing skin.'
Clinically proven to treat a huge array of hyperpigmentation and dark marks, this science-backed Skin Rocks serum has been formulated with a potent blend of proven pigmentation-fighting ingredients to help perfect the skin - and fast.
These include ingredients such as Tetrahydrodiferuloylmethane, Tetrapeptide-30 and Acetyl Glycyl Beta-Alanine, Hexylresorcinol and Ethyl Linoleate, Niacinamide, and 3-O-Ethyl Ascorbic Acid, which work synergistically to reduce hyperpigmentation production from different angles.
From defending the skin against free radical damage and strengthening the skin barrier to reducing pigmentation and preventing it from occurring in the first place, this serum is the one-and-done solution you've been after.
And while the before and after photos are exceptional enough, Skin Rocks has the numbers to prove the serum's impressiveness, too.
In clinical trials, brown spots were reduced by up to 24 per cent after eight weeks – and consumer feedback is just as impressive, where among 117 participants using the serum daily, 83 per cent saw a more even skin tone in two weeks and 90 per cent noticed brighter skin in four weeks.
But it's not just the test subjects who have been seeing impressive results – reviewers already can't get enough of the Hyperpigmentation Serum, raving of the 'gentle', 'hydrating' and 'effective' results.
'Already seeing results on my hyperpigmentation after 2 weeks usage!' raved one impressive five-star reviewer. 'Can't wait to see what results prolonged usage will bring. Effective while being gentle and non-irritating to my sensitive skin - this is an absolute winner!'
Another added: 'Lovely serum, skin feels so hydrated after use. Sinks in really well and is a perfect base for the next skin care product. Looking forward to seeing results.'
'Has already lightened my sun spot in only two weeks! Very excited to see what happens over the next few weeks,' wrote a third.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
24 minutes ago
- Daily Mail
Groundbreaking new Shroud of Turin discovery PROVES centuries of Christians right about Jesus
A new analysis of the Shroud of Turin has provided strong scientific evidence that supports the biblical account of Jesus' burial. The Bible says Jesus' body was wrapped only in spices and a 14-foot linen cloth, believed by Christians to bear His image. However, a 1998 study determined Jesus' body was washed before burial, contradicting scripture. Now, Dr Kelly Kearse, an immunologist trained at Johns Hopkins University, reexamined the 'washing hypothesis' originally proposed by forensic pathologist Dr Frederick Zugibe. Dr Kearse tested human blood samples under post-mortem conditions like reduced clotting and increased acidity. Using ultraviolet light and a microscope camera, he studied how blood transfers to cloth in these states. His findings indicated that the bloodstains on the Shroud came from an unwashed body, matching Jewish burial customs in the Bible that forbid washing the bodies of those who died violently. These customs hold that all blood lost during trauma remains part of the body and must be buried with it. A key discovery was that serum halos, clear rings around blood clots, were visible on many wounds on the Shroud. These halos only form if blood began to clot before touching the cloth, proving the blood came directly from fresh, unwashed wounds. Dr Zugibe conducted his research based on a passage from The Lost Gospel According to Peter, also known as the Gospel of Peter, an early Christian text that is not part of the canonical Bible. It is considered an apocryphal or non-canonical gospel and is often classified among the New Testament apocrypha. 'And he took the Lord and washed him, and rolled him in a linen cloth, and brought him to his own tomb, which was called the Garden of Joseph,' The Lost Gospel According to Peter 6:8 reads. Using that text, Dr Zugibe argued that an unwashed, crucified body would be so saturated with blood that it would produce large, indistinct smudges on cloth. His study used accident victims and found that their wounds produced no clear impressions, even after rinsing. However, Dr Kearse pointed out that the Shroud shows well-defined stains and serum halos, a key detail that makes the washing hypothesis incompatible with observable evidence. Recent research has determined that as blood begins to clot, it forms a small blister of plasma, the clear component of blood. As drying continues, the serum migrates to the outer edges, forming a serum halo that becomes visible under ultraviolet light. In deceased individuals, blood does not clot properly, and its pH level drops, becoming more acidic. To simulate these post-mortem conditions in the lab, Dr Kearse adjusted blood samples to match the acidity found several hours after death, then allowed them to dry on skin. Under these conditions, low pH and poor clotting, serum halos did not form. However, when blood had a low pH but was allowed to clot naturally, the halos reappeared. This suggested the presence of serum halos on the Shroud supports the idea that the blood came from clotted, unwashed wounds rather than from blood oozing after washing. Ultimately, Dr Kearse concluded that no known process could produce the Shroud's precise blood patterns from a cleaned corpse. He also theorized that if the body had not been washed, the blood could have transferred to the Shroud in a few ways. One possibility is that thick, semi-liquid clots of fresh blood stuck to the cloth while still soft. Another is that dried blood on the body became rehydrated in the damp conditions of a cave tomb, allowing it to adhere to the linen. Some researchers have proposed that radiation pressure, possibly linked to the moment of Jesus' resurrection, could have caused the transfer of dried blood to the cloth. However, there is currently no scientific evidence to support this mechanism producing the stain patterns seen on the Shroud. Dr Kearse's findings do not prove the Shroud's authenticity but offer strong support for the biblical narrative of Jesus' burial. When first exhibited in the 1350s, the Shroud was touted as the actual burial cloth used to wrap the mutilated body of Christ following his crucifixion. Also known as the Holy Shroud, the linen bears a faint, full-body image of a bearded man, which many Christians believe to be a miraculous imprint of Jesus. However, radiocarbon dating performed in the 1980s placed the Shroud's origin in the Middle Ages, hundreds of years after Christ.
Telegraph
an hour ago
- Telegraph
Ozempic-style pill can help people lose two stone
A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of overweight and obese adults given the drug, which targets appetite receptors, found they lost significant amounts of weight and saw improvements in heart health. Orforglipron is part of a class of medications which has shown promise turning the tide on a host of conditions, including heart disease and strokes. The medicine works by targeting the same GLP-1 receptors as the drugs Ozempic, Wegovy and Mounjaro, which are given as injections. Orforglipron is the first pill of its kind to complete phase III trials, with previous oral medications having resulted in less weight loss and requiring complex food and water restrictions. The drug is expected to be available in the UK as soon as next year at a much lower cost than weight-loss injections. Manufacturer Eli Lilly has said it is confident they would be able to launch it globally without any supply constraints. Experts have said it could prove 'game-changing' with millions more people likely to opt for pills. The results announced by Eli Lilly come from a trial of 3,127 adults who were overweight or obese, and also had a weight-related medical problem, such as high blood pressure or heart disease. The drug has already shown good results in patients with type 2 diabetes. At 72 weeks, there was average weight loss of 27. 3lbs (12.4 kilos). And six in 10 participants lost at least 10 per cent of their body weight. Separate trials have shown other injections have caused greater weight loss - with average loss of almost three and half stone (22 kilos) for those on the highest dose of Mounjaro. But the convenience of a daily pill, and a lower cost, is likely to appeal to an even greater market than those taking injections. The trial also found that orforglipron was associated with reductions in known markers of cardiovascular risk, including non-HDL cholesterol, triglycerides and systolic blood pressure in pooled analyses across all doses. Detailed results will be presented next month at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 in Vienna. Obesity affects 1 billion people worldwide Kenneth Custer, president of Eli Lilly Cardiometabolic Health, said: ' Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than 1 billion people worldwide.' 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, a senior lecturer in physiology at Anglia Ruskin University, said: 'These preliminary results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of these class of drugs. 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10 per cent weight loss at the highest dose. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients. The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.'
BBC News
an hour ago
- BBC News
Western Isles Council fined after death of care home resident
A council has been fined £80,000 after the death of a patient who went missing from one of its care homes in the Western MacLeod, who was 69 and had dementia, left St Brendan's Care Home in Barra by the only door in the building that was not fitted with an was missing for about four hours before a coastguard helicopter found him in the early hours of 9 March last year on the patio of a house near the home. He died in hospital a short time authority Comhairle nan Eilean Siar, which has pleaded guilty to health and safety breaches, said it wished to express its condolences to Mr MacLeod's family. The council was fined at Lochmaddy Sheriff Court in North Uist on court heard that Mr MacLeod had been placed in the council-operated care home in October 2023 so he could be closer to one of his observed his behaviour during his first month in the home to help them better understand the care he 8 March 2024, he was settled into his bed at about 21:00 and hourly checks were made of his was found empty at 02:00 on 9 March, and searches were made of the court heard that to avoid being detected by staff, Mr MacLeod had left the building using an exit about 10m (33ft) from his room and not fitted with an alarm. Electronic tag Workers at the home alerted Police Scotland and a search involving coastguard, RNLI and fire service personnel was launched of the surrounding area.A coastguard helicopter fitted with heat detection equipment found Mr MacLeod at about 06:00. He had facial injuries consistent with falling to the ground. Despite the efforts of medical staff he died an hour later.A Health and Safety Executive (HSE) investigation found that he had made several previous attempts to leave the home. Carers had tried fitting an electronic tag to Mr MacLeod's clothing to track his movements but he would manage to find the device and remove said after Mr MacLeod's death St Brendan's Care Home introduced a regime of half hourly checks on also said arrangements had been made to install keypad entry systems on all doors but this work had not been completed before Mr MacLeod went sentencing, HSE inspector Ashley Fallis said: "This was a tragic and preventable death."The council should have made sure the home had stronger measures in place with Mr MacLeod's risks already known and assessed."Although changes have since been made, they came too late to prevent his death." Door security Comhairle nan Eilean Siar said it accepted that health and safety shortcomings contributed to the incident.A spokesperson said: "Comhairle nan Eilean Siar once again extends its sincere condolences to the family and friends of the late Mr Allan Macleod for the circumstances surrounding his tragic passing on 9 March 2024."The comhairle hopes that the conclusion of this case will offer the family some closure."The local authority said the door security system in use at St Brendan's Care Home was a key factor in this case. A new security system had been purchased, but at the time of the incident the work to install it had not been spokesperson said: "Comhairle nan Eilean Siar is committed to the delivery of high standards of care to all residents in our residential homes. "In this instance these standards were not fully met."They said the comhairle had implemented health and safety improvements and would continue to work with the Care Inspectorate to ensure its residential homes operated to the highest possible standards.
